Pain can really mess up our day, from the moment we wake, until we (hopefully) fall asleep at night. Pain can actually feel worse at night and have a horrible effect on a good night’s sleep, and there is nothing worse than lying awake in pain.
We all have pain at one time or another, whether it’s a headache, arthritis, nerve pain, muscle pain, joint pain, carpal tunnel, neck pain, neuropathy, postsurgical pain, chronic pain, fibromyalgia or other. Whatever the pain, it is always due to inflammation.
Photobiomodulation (sometimes called red light therapy, infrared light therapy or low level light therapy) is a process in which a deeply penetrating light is absorbed by the photoacceptors in the compromised cell’s mitochondria, energizing our adenosine triphosphate (ATP)—the fuel that drives our cells. This boost of cellular energy results in a cascade of metabolic changes that lead to an increase in micro-circulation, tissue repair and a decrease in inflammation and pain, along with many other therapeutic benefits. These benefits may include diabetic wound healing, as well as helping many skin issues such as aging, acne, bruising, eczema, psoriasis, cold sores and shingles.
Now, due to science, research and modern technology, there is a way to treat our inflammation and pain (and heal at the same time) at home without prescription medications, trips to the doctor for injections (that don’t always work), physical therapy or often unnecessary or ineffective surgeries. A light panel device, such as Celluma, can be used while relaxing at home, reading a book, watching TV or even taking a nap. It is easy, effective, beneficial and affordable.
Celluma is the only FDA approved panel cleared to treat with blue, red and infrared light simultaneously. It is safe, effective, drug-free, non-invasive, portable, cordless and available for home use.
Patricia Turney, of Patricia Turney Esthetics, uses the Celluma device in her office and is offering complimentary treatments. Connect at 520-247-3535 or PatriciaTurneyEsthetics.com. See ad, page 12.